2025-04-08 19:19:43
Latest Post
Godrej Properties delivers its highest ever quarterly and full year bookings
Poonawalla Fincorp Launches Shopkeeper Loan Business
Revolt Motors Expands to 200 Dealerships, Targets 400 by FY26
Sobha Ltd - Real Estate Operational Update - Q4 FY 2024-25
Lemon Tree Hotels signs a new property in DarjeelingStock Report
Concord Drugs Q3FY22 PAT at Rs. 42.14 lakhs
Posted On : 2022-02-16 19:55:41( TIMEZONE : IST )
Concord Drugs Ltd has reported Standalone financial results for the period ended December 31, 2021.
Financial Results (Q3 FY2022) - QoQ Comparison
The company has reported total income of Rs. 13.4693 crores during the period ended December 31, 2021 as compared to Rs. 9.8588 crores during the period ended September 30, 2021.
The company has posted net profit / (loss) of Rs. 0.4214 crores for the period ended December 31, 2021 as against net profit / (loss) of Rs. 0.4579 crores for the period ended September 30, 2021.
The company has reported EPS of Rs. 0.482 for the period ended December 31, 2021 as compared to Rs. 0.52 for the period ended September 30, 2021.
| Financials | Q3 FY2022 | Q2 FY2022 | % Change |
| Total Income | ₹ 13.4693 crs | ₹9.8588 crs |  36.62% |
| Net Profit | ₹0.4214 crs | ₹0.4579 crs |  -7.97% |
| EPS | ₹0.482 | ₹0.52 | -7.31% |
Financial Results (Q3 FY2022) - YoY Comparison
The company has reported total income of Rs. 13.4693 crores during the period ended December 31, 2021 as compared to Rs.8.2474 crores during the period ended December 31, 2020.
The company has posted net profit / (loss) of Rs.0.4214 crores for the period ended December 31, 2021 as against net profit / (loss) of Rs.2.6984 crores for the period ended December 31, 2020.
The company has reported EPS of Rs.0.482 for the period ended December 31, 2021 as compared to Rs.3.09 for the period ended December 31, 2020.
| Financials | Q3 FY2022 | Q3 FY2021 | % Change |
| Total Income | ₹ 13.4693 crs | ₹8.2474 crs | 63.32% |
| Net Profit | ₹0.4214 crs | ₹2.6984 crs | -84.38% |
| EPS | ₹0.482 | ₹3.09 | -84.40% |
Financial Results (9 Months Ended FY2022) - YoY Comparison
The company has reported total income of Rs.43.5691 crores during the 9 Months period ended December 31, 2021 as compared to Rs.43.0838 crores during the 9 Months period ended December 31, 2020.
The company has posted net profit / (loss) of Rs.1.5670 crores for the 9 Months period ended December 31, 2021 as against net profit / (loss) of Rs.2.9445 crores for the 9 Months period ended December 31, 2020.
The company has reported EPS of Rs.1.79 for the 9 Months period ended December 31, 2021 as compared to Rs.3.09 for the 9 Months period ended December 31, 2020.
| Financials | 9 Months Ended FY2022 | 9 Months Ended FY2021 | % Change |
| Total Income | ₹43.5691 crs | ₹43.0838 crs | 1.13% |
| Net Profit | ₹1.5670 crs | ₹2.9445 crs | -46.78% |
| EPS | ₹1.79 | ₹3.09 | -42.07% |
Shares of Concord Drugs Ltd was last trading in BSE at Rs. 30.70 as compared to the previous close of Rs. 29.95. The total number of shares traded during the day was 2328 in over 55 trades.
The stock hit an intraday high of Rs. 31.40 and intraday low of 29.00. The net turnover during the day was Rs. 72003.00.
